Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Trastuzumab with Radiation in Bladder Cancer
NCT00238420Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2005
- Primary completion
- Feb 2014
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 2, open-label trial of Paclitaxel Micelles for Injection and trastuzumab in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Acute Treatment-related Toxicity at 90 days. Started Jul 2005; status: completed.
02
Drugs
Paclitaxel Micelles for Injectiontrastuzumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT00238420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238420.